Condition: Spondylarthropathies · Sponsor: Centre Hospitalier Universitaire de Nīmes
Idiopathic juvenile arthritis includes 20% of patients with arthritis with enthesitis or juvenile spondyloarthropathy. This is treated with anti-inflammatory drugs and then followed by biotherapy with DMARDs (Drugs Modifying the Activity of Rheumatic Disease) if the former are insufficient. Methotrexate (MTX) may also be used before these biotherapies. Recently, in adults, a particular profile of intestinal microbiota has been shown to alter the availability of MTX making it in efficient. Knowing that pediatric patients with juvenile spondyloarthropathy have an imbalance of their intestinal flora (dysbiosis) the investigators wanted to explore whether DMARDs could have a similar impact on the microbiota of these young patients and alter the response to treatment.
This description comes directly from the study's public registry record.
Tu-Anh TRAN, Professor · +33 4 66 32 86 · tu.anh.tran@chu-nimes.fr
Jean-Philippe LAVIGNE, Professor · +334 66 68 32 02 · jean.philippe.lavigne@chu-nimes.fr
Always discuss trial participation with your own doctor first.
| Nîmes University Hospital | Nîmes, Gard, France | Recruiting |
| Montpellier University Hospital, Arnaud de Villeneuve Hospital | Montpellier, Hérault, France | Recruiting |
| APHM, Hopital Nord | Marseille, France | Recruiting |
| Hopital des enfants, CHU de Toulouse | Toulouse, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04540432